Novartis AG (VTX:NOVN) has been given a CHF 87 price target by research analysts at S&P Global in a research report issued on Tuesday. The brokerage currently has a “neutral” rating on the stock.

NOVN has been the subject of a number of other research reports. Deutsche Bank AG set a CHF 81 target price on shares of Novartis AG and gave the stock a “neutral” rating in a research report on Wednesday, July 19th. HSBC Holdings plc set a CHF 90 target price on shares of Novartis AG and gave the stock a “buy” rating in a research report on Tuesday, September 19th. Baader Bank set a CHF 90 target price on shares of Novartis AG and gave the stock a “buy” rating in a research report on Tuesday. UBS AG set a CHF 76 target price on shares of Novartis AG and gave the stock a “neutral” rating in a research report on Tuesday, July 18th. Finally, Sanford C. Bernstein set a CHF 94 target price on shares of Novartis AG and gave the stock a “buy” rating in a research report on Tuesday, July 18th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and seven have given a buy rating to the stock. Novartis AG currently has an average rating of “Hold” and an average target price of CHF 85.70.

Shares of Novartis AG (VTX:NOVN) traded down 2.99% during trading on Tuesday, reaching CHK 82.60. The company’s stock had a trading volume of 8,514,197 shares. The firm’s 50-day moving average price is CHK 83.04 and its 200-day moving average price is CHK 80.14. The company has a market capitalization of CHK 193.52 billion and a price-to-earnings ratio of 30.16. Novartis AG has a one year low of CHK 67.40 and a one year high of CHK 85.05.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece on another publication, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/10/24/novartis-ag-novn-given-a-chf-87-price-target-by-sp-global-analysts.html.

About Novartis AG

Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.

Analyst Recommendations for Novartis AG (VTX:NOVN)

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.